Sugi Predict

Sugi Predict / Compounds / SCHEMBL4245171

SCHEMBL4245171

SCHEMBL4245171

N=C(N)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2[nH]cnc(=O)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.45
▸ HTT P42858 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ GALR3 O60755 1/20 0.45
▸ S1PR4 O95977 1/20 0.45
▸ S1PR1 P21453 1/20 0.45
▸ PAX8 Q06710 1/20 0.45
▸ TP53 P04637 3/20 0.44
▸ BLM P54132 2/20 0.44
▸ PNP P00491 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ MTOR P42345 2/20 0.44
▸ GMNN O75496 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ DNMT1 P26358 1/20 0.44
▸ THPO P40225 1/20 0.44
▸ HBB P68871 1/20 0.44
▸ PMP22 Q01453 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7213418 0.92 ALDH1A1 (0.50) ALDH1A1HTTMAPTRAB9ANPC1
SCHEMBL4245177 0.83 ALDH1A1 (0.55) ALDH1A1HTTMAPTRAB9ANPC1
Hydrochloric Acid SCHEMBL6743468 0.82 ALDH1A1 (0.54) ALDH1A1HTTMAPTRAB9ANPC1
SCHEMBL28559365 0.80 PAX8 (0.48) ALDH1A1HTTMAPTRAB9APAX8
SCHEMBL7213421 0.74 ALDH1A1 (0.57) ALDH1A1HTTMAPTRAB9ANPC1
Inosine SCHEMBL7633338 0.74 PAX8 (0.57) ALDH1A1HTTMAPTRAB9APAX8
Inosine SCHEMBL15903470 0.74 PAX8 (0.57) ALDH1A1HTTMAPTRAB9APAX8
Inosine SCHEMBL568027 0.74 PAX8 (0.57) ALDH1A1HTTMAPTRAB9APAX8
Inosine SCHEMBL1682742 0.74 PAX8 (0.57) ALDH1A1HTTMAPTRAB9APAX8
Inosine SCHEMBL20138538 0.74 PAX8 (0.57) ALDH1A1HTTMAPTRAB9APAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813278-B9 Nucleoside analogs with carboxamidine modified monocyclic base VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2015-04-01 — — EP disclosed
EP-1813278-B1 Nucleoside analogs with carboxamidine modified monocyclic base VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2014-10-29 — — EP disclosed
US-7638496-B2 Viramidine (Ribamidine HCL) to treat infections, infestations, tumors and hypersensitivities to autoimmune diseases; viricide; prodrug; less toxic than Ribavirin; selective modulation of Type 1 and Type 2 responses relative to one another for a bimodal effect VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-12-29 — — US disclosed
US-20090176721-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-07-09 — — US disclosed
EP-1257281-B8 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE VALEANT PHARMACEUTICALS NORTH (US) 2008-01-23 — — EP disclosed
EP-1257281-B1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE RIBAPHARM INC (US) 2007-11-07 — — EP disclosed
EP-1813278-A1 Nucleoside analogs with carboxamidine modified monocyclic base Ribapharm, Inc. (US) 2007-08-01 — — EP disclosed
US-20050159372-A1 Nucleoside analogs with carboxamidine modified monocyclic base VALEANT CANADA LP (CA) 2005-07-21 — — US disclosed
US-6831069-B2 Having substituents at the C4' and C5' positions of the ribofuranose moiety; anticancer and immunomodulating effects at reduced cytotoxicity; treating autoimmune diseases, cancer, dermatitis RIBAPHARM INC. 2004-12-14 — — US disclosed
EP-1363581-A2 PYRROLO(2,3-D)PYRIMIDINE NUCLEOSIDE ANALOGS Ribapharm, Inc. (US) 2003-11-26 — — EP disclosed
EP-1278528-A4 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE-MODIFIED BICYCLIC BASE TAM ROBERT (US) 2003-03-19 — — EP disclosed
EP-1257281-A4 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE ICN PHARMACEUTICALS (US) 2003-03-19 — — EP disclosed
EP-1278528-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE-MODIFIED BICYCLIC BASE ICN Pharmaceuticals, Inc. (US) 2003-01-29 — — EP disclosed
WO-2002100354-A2 PYRROLO[2,3-D]PYRIMIDINE NUCLEOSIDE ANALOGS RIBAPHARM INC. (US) 2002-12-19 — — WO disclosed
EP-1257281-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE ICN Pharmaceuticals, Inc. (US) 2002-11-20 — — EP disclosed
US-20020035077-A1 Pyrrolo[2,3-d]pyrimidine nucleoside analogs CEQUENT PHARMACEUTICALS, INC. 2002-03-21 — — US disclosed
WO-2001060381-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE-MODIFIED BICYCLIC BASE RIBAPHARM CORP. (US) 2001-08-23 — — WO disclosed
WO-2001060379-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE RIBAPHARM CORP. (US) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035077-A1 Pyrrolo[2,3-d]pyrimidine nucleoside analogs TYMP, DPYD, TYMS ALDH1A1 2327/4885HTT 3587/4885MAPT 4381/4885
US-20090176721-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE NT5C2, PNP, SLC29A1 ALDH1A1 1998/4885HTT 4301/4885MAPT 4107/4885
US-20050159372-A1 Nucleoside analogs with carboxamidine modified monocyclic base NT5C2, PNP, SLC29A1 ALDH1A1 1998/4885HTT 4301/4885MAPT 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.